Title: Prevalence and genotypes distribution of group A rotavirus among outpatient children
under five years with acute diarrhea in Shanghai, China, 2012-2018
Version: 3 Date: 13 Feb 2022
Reviewer's report:
Overview
This study describes the prevalence of rotavirus genotypes from 1,814 samples collected among
children <5 year with acute diarrhea during 2012-2018 in Shanghai, China. Although such
studies have become routine, it is especially timely to document the prevalence of rotavirus
types in Asian Countries because of the licensure of a vaccine for use in China. The continuation
of these studies will help document strain prevalence after vaccine introduction and assess the
impact of vaccine programs on strain incidence.  In addition, these studies will be valuable to
assess the need to introduce new rotavirus vaccine platforms, and to plan for effective rotavirus
vaccine programs in China in the future.
The manuscript was very well described, clear and addressed all relevant data of the surveillance
group A rotavirus in children with acute diarrhea.
I suggest that the authors review the few points described below:
Line 249, This phenomenon could be related to the protective “maternal” immunity against RVA
obtained in children less than 6 months.
I consider it important the authors discuss the findings of genotypes G/P that are not included
in the vaccine currently used in China (LLR Lanzhou Lamb Rotavirus (LLR) vaccine rotavirus
G10P[12].  Include in the discussion the possibility of introducing the new trivalent live
human-lamb reassortant rotavirus vaccine (LLR3) in the Program on Immunization routine
immunization schedule in China.
I encourage authors to study the prevalence of human RVA (and genotypes) in samples collected
from children hospitalized with severe gastroenteritis in Shanghai.
Title: Prevalence and genotypes distribution of group A rotavirus among outpatient children
under five years with acute diarrhea in Shanghai, China, 2012-2018
Version: 3 Date: 13 Feb 2022
Reviewer's report:
Overview
This study describes the prevalence of rotavirus genotypes from 1,814 samples collected among
children <5 year with acute diarrhea during 2012-2018 in Shanghai, China. Although such
studies have become routine, it is especially timely to document the prevalence of rotavirus
types in Asian Countries because of the licensure of a vaccine for use in China. The continuation
of these studies will help document strain prevalence after vaccine introduction and assess the
impact of vaccine programs on strain incidence.  In addition, these studies will be valuable to
assess the need to introduce new rotavirus vaccine platforms, and to plan for effective rotavirus
vaccine programs in China in the future.
The manuscript was very well described, clear and addressed all relevant data of the surveillance
group A rotavirus in children with acute diarrhea.
I suggest that the authors review the few points described below:
Line 249, This phenomenon could be related to the protective “maternal” immunity against RVA
obtained in children less than 6 months.
I consider it important the authors discuss the findings of genotypes G/P that are not included
in the vaccine currently used in China (LLR Lanzhou Lamb Rotavirus (LLR) vaccine rotavirus
G10P[12].  Include in the discussion the possibility of introducing the new trivalent live
human-lamb reassortant rotavirus vaccine (LLR3) in the Program on Immunization routine
immunization schedule in China.
I encourage authors to study the prevalence of human RVA (and genotypes) in samples collected
from children hospitalized with severe gastroenteritis in Shanghai.
Please review this paper.
user
Title: Prevalence and genotypes distribution of group A rotavirus among outpatient children
under five years with acute diarrhea in Shanghai, China, 2012-2018
Version: 3 Date: 13 Feb 2022
Reviewer's report:
Overview
This study describes the prevalence of rotavirus genotypes from 1,814 samples collected among
children <5 year with acute diarrhea during 2012-2018 in Shanghai, China. Although such
studies have become routine, it is especially timely to document the prevalence of rotavirus
types in Asian Countries because of the licensure of a vaccine for use in China. The continuation
of these studies will help document strain prevalence after vaccine introduction and assess the
impact of vaccine programs on strain incidence.  In addition, these studies will be valuable to
assess the need to introduce new rotavirus vaccine platforms, and to plan for effective rotavirus
vaccine programs in China in the future.
The manuscript was very well described, clear and addressed all relevant data of the surveillance
group A rotavirus in children with acute diarrhea.
I suggest that the authors review the few points described below:
Line 249, This phenomenon could be related to the protective “maternal” immunity against RVA
obtained in children less than 6 months.
I consider it important the authors discuss the findings of genotypes G/P that are not included
in the vaccine currently used in China (LLR Lanzhou Lamb Rotavirus (LLR) vaccine rotavirus
G10P[12].  Include in the discussion the possibility of introducing the new trivalent live
human-lamb reassortant rotavirus vaccine (LLR3) in the Program on Immunization routine
immunization schedule in China.
I encourage authors to study the prevalence of human RVA (and genotypes) in samples collected
from children hospitalized with severe gastroenteritis in Shanghai.
assistant